Safety and Clinical Performance of the Protecta ICD and CRT-D

Not Applicable

Completed

Brief Summary: The purpose of the study is two-fold. In Phase I (Protecta Clinical Study), system performance will be evaluated. In Phase II (PainFree SST), the inappropriate shock-free rate at one year of subjects implanted with a Medtronic Protecta implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) will be evaluated.

Detailed Description: The PainFree SST study was a prospective, multicenter clinical trial, which was conducted in two consecutive phases. Phase I assessed safety as determined by assessment of delays in ventricular fibrillation (VF) arrhythmia detection time using new algorithms. Phase II assessed the influence of new algorithms on inappropriate and unnecessary shocks at 1 year of follow-up. Subjects enrolled in Phase I continued in Phase II of the study and data from all enrolled subjects contributed to the analysis of Phase II objectives. A sub-study of Phase II randomized secondary prevention subjects to either 18/24 NID or 30/40 NID in order to assess the safety of prolonged detection in these patients.

Recruitment & Eligibility

Inclusion Criteria

Patients meeting one of the following criteria can be included in Phase I of the study:
- Patients indicated (per local indications) for a dual chamber implantable cardioverter defibrillator (DR-ICD)/cardiac resynchronization therapy defibrillator (CRT-D)
- Patients undergoing a device replacement or upgrade to DR-ICD or CRT-D and with the protocol required leads (patients must be enrolled prior to implant)
Patients meeting one of the following criteria can be included in Phase II of the study:
- Patients indicated for a DR-ICD/VR-ICD/CRT-D device and intended to receive a Protecta device
- Patients undergoing a DR-ICD/VR-ICD/CRT-D device replacement or an upgrade to a Protecta DR-ICD/VR-ICD or CRT-D
- Patients indicated for a DR-ICD/VR-ICD/CRT-D already implanted with a Protecta device and the protocol required leads, who have not yet been discharged after implant

Exclusion Criteria

Patients with a mechanical tricuspid heart valve
Patients enrolled or intended to participate in any concurrent drug and/or device study, which would confound the results of this trial as determined by Medtronic, during the course of this clinical study
Patients with medical conditions that preclude the testing required for all patients by the study protocol or that otherwise limit study participation required for all patients
Patients with exclusion criteria required by local law (e.g. age, pregnancy, breast feeding, etc)
Patients anticipated not being able to complete the study
Patients unwilling to provide written informed consent

Primary Outcome Measures

Name	Time	Method
Percentage of Subjects Who Are Inappropriate Shock Free	Implant to one year post-implant	Primary objective of Phase II. Subjects implanted with a VR device will be analyzed separately from subjects implanted with a DR / CRT-D device. An inappropriate shock is a shock delivered by the defibrillator when the patient's heart rhythm was not a tachyarrhythmia, as adjudicated by the independent Episode Review Committee .
Percentage of Subjects With Unanticipated Severe Adverse Device Effects (Phase I)	Implant to one month post-implant	In Phase I, only DR-ICD/CRT-D devices were implanted, so that for Phase I objectives there is only 1 arm to report results for.
Percentage of Phase I Subjects Where the Ventricular Fibrillation (VF) Detection Time With Protecta Features on is no More Than 2 Seconds Longer Than the VF Detection Time With Protecta Features Off	At implant	In Phase I, only DR-ICD/CRT-D devices were implanted, so that for Phase I objectives there is only 1 arm to report results for.

Secondary Outcome Measures

Name	Time	Method
Percentage of Secondary Prevention Subjects Who Are Syncopal Event Free	Implant to one year post-implant

Locations (122): Birmingham Heart Clinic PC
🇺🇸
Birmingham, Alabama, United States
CardioVasular Associates of Mesa
🇺🇸
Mesa, Arizona, United States
Mercy Hospital Fort Smith
🇺🇸
Fort Smith, Arkansas, United States
LA Cardiology Associates
🇺🇸
Los Angeles, California, United States
Cardiology Consultants of Napa Valley
🇺🇸
Napa, California, United States
Hartford Hospital
🇺🇸
Hartford, Connecticut, United States
University of Florida Health at Jacksonville
🇺🇸
Jacksonville, Florida, United States
Arrhythmia Syncope Consultants LLC
🇺🇸
Miami, Florida, United States
Indiana Heart Physicians
🇺🇸
Indianapolis, Indiana, United States
Cardiovascular Research of Northwest Indiana
🇺🇸
Munster, Indiana, United States
Scroll for more (112 remaining)
Birmingham Heart Clinic PC
🇺🇸Birmingham, Alabama, United States